Objectives: Acute cough/lower respiratory tract infection (LRTI) is one of the commonest reasons for consulting and antibiotic prescribing. There are theoretical reasons why treatment with particular antibiotic classes may aid recovery more than others, but empirical, pragmatic evidence is lacking. We investigated whether treatment with a particular antibiotic class (amoxicillin) was more strongly associated with symptom score resolution and time to patients reporting recovery than each of eight other antibiotic classes or no antibiotic treatment for acute cough/LRTI.
Introduction
Controversy surrounds which class of antibiotics should be selected once clinicians have made a decision to prescribe antibiotics for acute cough/LRTI in primary care. While trials and observational studies generally show that there is little or no benefit from antibiotic treatment of acute cough in primary care, 1 antibiotic prescribing remains common practice for this condition. 2 The European Respiratory Society (ERS) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the management of adult lower respiratory tract infections (LRTIs) 3 promote a conservative approach to antibiotic treatment for otherwise well people in the community and recommend amoxicillin or tetracycline as first-line agents for certain patients: those with suspected or definite pneumonia; those with selected exacerbations of chronic obstructive pulmonary disease (patients with three of the following symptoms: increased dyspnoea; increased sputum volume; and increased sputum purulence); those aged over 75 years with fever; those with cardiac failure; those with insulin-dependent diabetes mellitus; and those with serious neurological disorder. However, these guidelines indicate that there is insufficient robust empirical evidence for their recommendations about antibiotic choice, which were based on expert consensus. The US CDC treatment guideline for acute cough illness recommends against empirical antibiotics for acute bronchitis. 4 A recent systematic review concluded that there is insufficient evidence to recommend one antibiotic class over another for the treatment of community-acquired pneumonia. 5 Some general medical practitioners prescribe newer, broad-spectrum agents early because they believe these agents will give the patient the best chance of rapid cure and prevent hospital admissions. 6 Also, the use of agents such as fluoroquinolones for acute cough/LRTI is sometimes justified on the basis of differences in regional bacterial resistance rates. 6 The anti-inflammatory properties of macrolides are mentioned as a reason to select these agents. 7 We therefore analysed data from the 13 country GRACE (Genomics to combat Resistance against Antibiotics in Community-acquired LRTI in Europe), 8 an observational study of the presentation, management and outcome of acute cough/LRTI in primary care to determine whether any antibiotic class is associated with clinically meaningful differences in symptom resolution. We planned to do this by investigating whether treatment with any individual antibiotic class (or no antibiotic treatment) was associated with either differences in daily symptom scores or time until patients reported recovery when compared with treatment with amoxicillin, as this is the most commonly recommended and prescribed antibiotic for acute cough/LRTI in Europe. 2 
Patients and methods

Patients
Eligible patients were aged 18 years and over, consulting with an illness where an acute or worsened cough was the main or dominant symptom, or had a clinical presentation that suggested an LRTI, with a duration of up to and including 28 days. Participating general practitioners (GPs) 
Data
Clinicians recorded aspects of the patients' history, symptoms, co-morbidities (diabetes, chronic lung disease and cardiovascular disease), clinical findings and management, including antibiotic prescription and other treatments and investigations, on a case report form (CRF). Regarding antibiotic treatment, clinicians were asked whether antibiotic treatment was prescribed and, if so, for the details. Where additional antibiotics were included in answers to questions about prescribing other treatments, these were noted. GPs indicated the presence or absence of 14 symptoms (cough, sputum production, shortness of breath, wheeze, coryza, fever during this illness, chest pain, muscle aching, headache, disturbed sleep, feeling generally unwell, interference with normal activities, confusion/disorientation and diarrhoea) and then rated whether each of the symptoms constituted 'no problem', a 'mild problem', a 'moderate problem' or a 'severe problem' for the patient. Patients were given a symptom diary. They were asked to rate 13 symptoms each day until symptom resolution (or for 28 days if symptoms were ongoing) on a seven-point scale comprising the following responses: 'normal/not affected'; 'very little problem'; 'slight problem'; 'moderately bad'; 'bad'; 'very bad'; and 'as bad as it can be'. Patients rated the same symptoms as the clinicians except for confusion/disorientation and diarrhoea. In addition they were asked to rate the impact of their illness on their social activities. A symptom severity score was calculated by summing these scores and scaling them to range between 0 and 100. Patients were also asked to indicate the day on which they felt recovered from their illness. If they did not feel recovered after 28 days, this was recorded.
Sample size
The sample size for the study was based on estimating proportions in each network, in order to investigate network variation as reported previously. 2 We used all available data in analyses, such as in the current study of association of treatment by antibiotic class with outcome.
Analysis
Antibiotics prescribed by clinicians were grouped according to the following classes: tetracyclines; amoxicillin; cephalosporins; sulphonamides/trimethoprim; macrolides/lincosamides; quinolones; phenoxymethylpenicillin/penicillin G; co-amoxiclav; and other.
We investigated the association between antibiotic class and (i) the daily total symptom severity scores across the 28 days and (ii) the day patients reported recovery. For both analyses, treatment with amoxicillin was compared with each of the other eight antibiotic classes as well as no antibiotic treatment. Daily total symptom severity scores (logtransformed to improve model fit; 1 was added to the symptom scores to cope with zeroes) were modelled using a three-level autoregressive moving average model (ARMA) (1,1) model, with symptom scores nested within patients nested within clinicians and lags being previous day's symptom scores. Time to the day patients reported recovery was modelled using a two-level hierarchical Cox proportional hazards survival analysis. This approach naturally accounts for censored data. All models were controlled for differences in clinical presentation using 13 of the 14 clinician-recorded symptoms at index consultation (cough was excluded as it was an inclusion criterion), sputum colour, temperature, age and co-morbidities, along with smoking status and duration of illness prior to the consultation. All analyses were complete case analyses. Analysis was undertaken in the R programming language and environment using the nlme package and survival packages. 9 -11 Standard diagnostics were performed for all models, indicating adequate model fit.
Results
Three hundred and eighty-seven practitioners recruited a total of 3402 patients. Four patients were later found to be ineligible and were therefore excluded from further analysis. CRFs were completed for 3368 (99%) and diary data were obtained from 2714 (80%) patients. Excluding patients with missing data reduced the CRF dataset to 3296 (97%) and the diary dataset to 2469 (73%) (missing by symptom: phlegm production, n¼ 75; shortness of breath, n¼ 4; wheeze, n¼ 6; coryza, n¼ 11; fever, n¼ 18; chest pain, n¼ 7; muscle aching, n¼11; headache, n¼ 8; disturbed sleep, n ¼18; feeling generally unwell, n¼ 13; interference in normal activities, n¼ 13; confusion/disorientation, n¼ 4; diarrhoea, n¼5; temperature, n¼ 20; and smoking status, n¼ 3). Patients who returned the diary data were generally older (median age 48 years versus 36 years) and more frequently prescribed antibiotics (54% versus 46%), but were otherwise similar, as shown in Table 1 .
Of those who responded to the diary, 222 (6.5%) did not respond to the question 'on what day did you feel recovered', reducing the sample size for the survival analysis to 2319. This is summarized in the participant flow chart in Figure 1 . After 28 days 216 (6.3%) patients did not feel they had recovered.
There was wide variation in the numbers treated with different antibiotics. Of the 1464 patients who received antibiotics, 7 received a prescription for an additional antibiotic at the index consultation. We analysed these 7 patients according to the antibiotic that the clinician listed in the CRF under 'antibiotic treatment' and we did not take into account the antibiotic prescriptions listed under 'other treatment'. Most patients were treated with macrolides/lincosamides (n¼ 386) or amoxicillin (n¼ 379) ( Table 1) . Table 2 shows the number of patients treated with each antibiotic class and demographic features for Butler et al.
those patients and those not treated with antibiotics. The demographic features were similar for all these subgroups of patients. The unadjusted mean and median of their symptom severity scores in the 28 days after presentation is shown in Figure 2 . These trajectories illustrate the typical duration of the illness. The analysis of symptom severity scores over the 28 days after presentation shows that patients prescribed cephalosporins had marginally higher total symptom severity scores at baseline [coefficient: 0.26 (in the log scale), P value: 0.02] than patients prescribed amoxicillin, but no antibiotic treatment was significantly associated with improved recovery over time (Table 3) . No individual antibiotic class (as well as no antibiotic treatment) was associated with a significantly shorter time until patients reported recovery when compared with treatment with amoxicillin, as shown by the hazard ratios reported in Table 4 (P values ranging between 0.06 and 0.92, Table 4 ). Figure 3 shows Kaplan -Meier plots illustrating the proportion not recovered against time for those who received 'no antibiotic treatment', 'tetracyclines', 'cephalosporins', 'macrolides/lincosamides' or 'co-amoxiclav' and compares these with the survival curve for those treated with amoxicillin, along with 95% confidence limits. All of the 95% confidence limits contain the survival curve for those treated with amoxicillin, indicating no statistically significant difference in time to recovery for these treatment groups. The width of the 95% confidence intervals provides an indication of the precision of the estimates for each antibiotic class.
Discussion
In this prospective international study of adults with acute cough/LRTI in primary care, we found no clinically significant evidence for greater effectiveness of treatment from any particular major antibiotic class used in everyday European general medical practice. Analysis of both resolution of daily symptom severity scores indicating recovery rates and the survival analysis of the day on which patients reported they were fully recovered showed no meaningful differences between antibiotic classes and no antibiotic treatment compared with treatment with amoxicillin. These analyses controlled for clinician-recorded symptom severity, sputum type, temperature, age, days waited before presentation, co-morbidities (diabetes, chronic lung disease and cardiovascular disease) and smoking status. Macrolide/lincosamide antibiotics fared no better than any other antibiotic class and no antibiotic treatment. A previous analysis of this cohort showed no important differences in total symptom severity scores between patients treated and not treated with antibiotics. 2 We now show no association between treatment by antibiotic class and recovery. This is important because evidence of association between a particular antibiotic class and recovery may have been lost in analyses of association between treatment with any antibiotic and recovery.
Strengths and weaknesses
The advantages of an observational study include possible minimal selection bias. Some patients offered participation in certain trials decline because they might not wish to risk being randomized to placebo treatment. On the other hand, other patients decline because they do not accept the risk of being allocated to antibiotic treatment. In this study, treatment was 23 (280) 12 (151) 4 (47) 7 (85) 22 (273) 70 (858) 7 (87) 6.5 (3, 11) 32 (66) 25 (53) 6 (13) 11 (23) 21 (44) 62 (133) 17 (36) 31 (116) 16 (62) 5 (20) 6 (22) 17 (64) 69 (261) 13 (50) 35 (36) 19 (20) 6 (6) 15 (16) 17 (18) 63 (66) 20 (21) 4 (2, 6) 33 (3) 33 (3) 0 (0) 22 (2) 11 (1) 89 (8) 0 ( 26 (101) 11 (41) 4 (15) 11 (44) 15 (56) 64 (248) 21 (81) 32 (26) 29 (23) 6 (5) 15 (12) 10 (8) 60 (48) 30 ( (5) 15 (7) 2 (1) 9 (4) 15 (7) 74 (34) 11 (5) (2) 56 (5) 11 ( allocated according to the usual practice of the treating clinician. We were able to control for an important number of possible confounders using statistical modelling, including severity at presentation, sputum colour, temperature, age, co-morbidities, smoking status and duration of illness prior to the consultation. The advantages of a trial, where patients would be randomized to treatment with different antibiotic classes, include accounting for known as well as unknown possible confounders. Unknown confounders may have biased the results against a particular antibiotic class. Also, we are unable to be sure that differences in bacterial resistance across countries did not bias our results. It is possible that our broad inclusion criteria meant that many of the patients we recruited had a viral infection that would have been unlikely to benefit from antibiotic treatment. We did not attempt microbiological diagnosis in this observational study of routine practice. We did not consider actual antibiotic consumption. We only considered antibiotic prescribing at the initial consultation in our analyses. Due to the low numbers of patients prescribed some of the less frequently used classes of antibiotics, the lack of evidence supporting a difference for these classes should be interpreted with caution.
Comparison with other studies
Our findings confirm the view that there is unlikely to be any meaningful average advantage from treating acute cough/LRTI with any particular antibiotic class over another. This confirms the expert opinion-based recommendation in the European Respiratory Society-European Society of Clinical Microbiology and Infectious Diseases (ERS-ESCMID) guidelines that there is no evidence-based justification on the basis of effectiveness to promote empirical treatment of acute cough with one class of antibiotic over another. 3 A systematic review of the effectiveness of b-lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community-acquired pneumonia found a lack of evidence for improved clinical outcomes with antibiotics active against atypical pathogens.
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Implications for research and practice
We found no evidence for the effectiveness of one class of antibiotic over another for treating acute cough/LRTI in adults in primary care. We confirmed that treatment with a particular antibiotic class was not associated with meaningful clinical benefit compared with no antibiotic treatment or treatment with amoxicillin. This supports the view that empirical antibiotic treatment should be used with caution for acute cough/LRTI, and that if clinicians do decide to prescribe antibiotics, the decision about which antibiotic to use should be based primarily on considerations such as cost, incidence of side effects and impact on selection of resistant organisms. 
